FDA/CDC

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants

Publish date: July 24, 2019

 

Pages

Recommended Reading

Pregnancy did not increase Hodgkin lymphoma relapse rate
MDedge ObGyn
Triptorelin doesn’t prevent ovarian failure in young women treated for lymphoma
MDedge ObGyn
‘Strong evidence’ links obesity to cancers
MDedge ObGyn
FDA updates breast implant–associated lymphoma cases, risk
MDedge ObGyn
Pruritus linked to wide variety of cancers
MDedge ObGyn
FDA: 246 new reports on breast implant-associated lymphoma
MDedge ObGyn
FDA panel leans toward more robust breast implant surveillance
MDedge ObGyn
FDA panel calls for changes to breast implant rupture screening
MDedge ObGyn
Powerful breast-implant testimony constrained by limited evidence
MDedge ObGyn
FDA opts not to ban textured breast implants
MDedge ObGyn